It has been studied in relapsed AML in combination with high-dose cytarabine (FLA), with or without granulocyte-colony stimulating factor (G-CSF), with reported CR rates ranging from 46% to 63% [14,15,16] (Table 1). This evidence concerns the gene CSF3 and acute myeloid leukemia.